8legs: Food and drug administration

Your Followed Topics

#1 out of 2

FDA says Novo Nordisk's Wegovy TV ad contains false or misleading claims about the drug's benefits.
Agency requests immediate action, including potential cessation of misleading ads.
FDA says ad implies greater weight loss and broader life benefits without evidence.
Agency notes improper risk information presentation in the ad.
Novo Nordisk says the ad has run since launch but is not the Super Bowl spot.
Wegovy is a key product as Novo Nordisk competes with Eli Lilly in the GLP-1 market.
Wegovy's launch makes it a focal point of Novo Nordisk's market strategy in obesity.
More than 170,000 Americans are taking Wegovy, per Novo Nordisk statements.
FDA's action follows Bloomberg reporting on the letter.
Novo Nordisk also faces legal action against Hims & Hers over compounded Wegovy.

Vote 0

#2 out of 28.4K est. views

health15h ago

The FDA proposed adding bemotrizinol (Tinosorb S) as a permitted active ingredient in U.S. sunscreens, up to 6 percent.
Experts say bemotrizinol is photostable and well tolerated, potentially improving sunscreen usage.
Bemotrizinol could enable lighter, more cosmetically elegant formulas that encourage daily use.
The approval would help U.S. brands reformulate with BEMT to improve safety and efficacy.
The move could benefit diverse skin tones by reducing white cast from zinc oxide formulas.
Public comment on bemotrizinol’s proposed approval ended January 26, 2026.
OTC Monograph M020 would be amended to include BEMT in various sunscreen forms if approved.
Bemotrizinol is already widely used overseas, but US approval has lagged.
U.S. sunscreen regulation treats sunscreen as a drug, slowing innovation compared with overseas markets.
Experts believe bemotrizinol could help address gaps in sun safety knowledge and usage.

Vote 1

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.